Sanofi says Boehringer's ex-China CHC business is worth an estimated €1.6 billion and is a good fit with its existing business in terms of products and geographies, giving it much increased ...

Sanofi’s SNY stock has declined 10.2% in the past three months. However, a lot of this price decline was due to the downtrend of the overall drug and biotech sector, which performed poorly in the past ...

Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank ...

After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...

Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

Kennedy Jr. to run the Department of Health and Human Services. How do Sanofi CEO Paul Hudson and GSK CEO Emma Walmsley—who lead two of the top vaccine companies in the world—feel about the ...

Sanofi’s new products like novel recombinant factor VIII therapy, Altuviiio, respiratory syncytial virus (RSV) antibody, Beyfortus (in partnership with AstraZeneca [AZN]), Pompe disease therapy ...

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far so we are determined to hang on ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

Sanofi SA (Nasdaq: SNY) will pay Cytokinetics an undisclosed amount and take over exclusive rights of the drug — aimed at a genetic heart wall-thickening disease known as hypertrophic ...